Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
Diffuse large B-cell lymphoma is a most prevalent non-Hodgkin's lymphoma. Recently the
clinical results have been improved with new drugs and new modalities such as
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) every 2 weeks. Bortezomib
is well known to be effective for multiple myeloma and has been being tried for other
malignancies including lymphoma. The investigators will incorporate Bortezomib to CHOP every
2 weeks to further improve the clinical efficacy in diffuse large B-cell lymphoma.